From vaccines to vector control, how GSK and its partners are seeking solutions to one of the world's most pressing public ...

It came as the FTSE 100 giant revealed a rise in sales as weakness in its vaccine division was offset by growth in speciality medicines.

GSK has teamed up with the University of Oxford on a programme that will try to identify the molecular changes in cells in precancerous stages that could form the basis of vaccines to prevent full ...

British stocks rose on Monday, propelled by strong performances in the healthcare and consumer sectors. The blue-chip FTSE ...

The Trump administration's apparent vaccine skepticism and proposed tariffs on Pharma could significantly impact GSK plc's vaccine division and its overall profitability, despite CEO Walmsley's ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...